期刊
ONCOLOGIST
卷 12, 期 10, 页码 1178-1182出版社
ALPHAMED PRESS
DOI: 10.1634/theoncologist.12-10-1178
关键词
cutaneous manifestations; tyrosine kinase inhibitors; dermatologic toxicity; sorafenib; palmar-plantar erythrodysesthesia; hand-foot syndrome
类别
The development of multitargeted tyrosine kinase inhibitors has provided significant advances in the treatment of renal cell carcinoma. This case describes initial therapy for managing renal cell cancer with the administration of sorafenib, a multitargeted tyrosine kinase inhibitor. We report the development of localized palmar-plantar epidermal hyperplasia, a rare but significant cutaneous adverse event from sorafenib therapy. Mild-to-moderate dermatologic toxicity from sorafenib has been well described in the literature. We also review the current knowledge and the proposed hypothesis for the development of cutaneous events related to tyrosine kinase inhibitors. This particular case represents a unique form of dermatologic toxicity to sorafenib that has not previously been described in the literature.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据